Strategies to treat interferon-induced graft dysfunction after living donor liver transplantation for hepatitis C.

about

Daclatasvir and asunaprevir for recurrent hepatitis C following living donor liver transplantation with HIV co-infection.

P2860

Q50276219-52B362A4-C145-41AC-8C6E-A19A990BAB51

P2860

Strategies to treat interferon-induced graft dysfunction after living donor liver transplantation for hepatitis C.

Item

http://www.wikidata.org/entity/Q40705940

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Strategies to treat interferon ...... ansplantation for hepatitis C.

@en

type

Item

label

Strategies to treat interferon ...... ansplantation for hepatitis C.

@en

prefLabel

Strategies to treat interferon ...... ansplantation for hepatitis C.

@en

P1476

Strategies to treat interferon ...... ansplantation for hepatitis C.

@en

P2093

Huanlin Wang

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Kotoh

http://www.w3.org/2001/XMLSchema#string

Ken Shirabe

http://www.w3.org/2001/XMLSchema#string

Norihiro Furusyo

http://www.w3.org/2001/XMLSchema#string

Shinichi Aishima

http://www.w3.org/2001/XMLSchema#string

Shinji Shimoda

http://www.w3.org/2001/XMLSchema#string

Takasuke Fukuhara

http://www.w3.org/2001/XMLSchema#string

Takeo Toshima

http://www.w3.org/2001/XMLSchema#string

Tomoharu Yoshizumi

http://www.w3.org/2001/XMLSchema#string

Toru Ikegami

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype

Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil.

Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus.

Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant.

High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?

Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin.

Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients.

Immunosuppression and HCV recurrence after liver transplantation.

Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis?

Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection.

P2888

s12072-013-9496-2

P304

285-292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12072-013-9496-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yoshihiko Maehara

P577

2013-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26202510

http://www.w3.org/2001/XMLSchema#string

Strategies to treat interferon-induced graft dysfunction after living donor liver transplantation for hepatitis C.

about

P2860

P2860

Strategies to treat interferon-induced graft dysfunction after living donor liver transplantation for hepatitis C.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698